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Objectives: Antibody (Ab) expression in the lung is a major characteristic of a
protective immune response to airway infection. However how local Ab production
is regulated within the airway is poorly understood. Here we wished to determine
if the B lymphocyte differentiation factor BAFF, which supports B cell differen-
tiation and Ab production, is expressed in response to infection by Pseudomonas
aeruginosa.
Methods and Results: BAFF protein expression was measured by ELISA in BAL
samples from 12 Pseudomonas aeruginosa (PA) positive and 8 PA negative cystic
ﬁbrosis patients (mean age 8 yrs) and 7 healthy normal patients undergoing elective
surgery. BAFF expression was signiﬁcantly elevated in both the PA infected group
(p = 0.01, median 156 pg, range 23–469 pg) and non PA infected group (p = 0.01,
median 218 pg, range 57–2000 pg) in comparison to the control group (median 0,
range 0−13 pg). A murine model of PA infection (Carter et al. JID 2010;202:935–
942) was used to determine if BAFF expression is a component of the airway
immune response to PA. In these experiments BALB/c mice were infected with an
isolate of Liverpool epidemic strain, B65 and BAFF levels measured by ELISA in
lung extracts at zero, 15 minutes, 1, 2, 3 and 7 days, post infection (n = 5, all time
points). Signiﬁcantly elevated BAFF expression (P = 0.01) was observed at days I,
2 and 3 days post infection. Levels of the B cell chemoattractant CXCL13 were
similarly signiﬁcantly elevated at day 1.
Conclusions: BAFF expression is a consistent feature of the airway response to PA
and to bacterial infection. This is indicative of a role for BAFF in the production
of protective Ab within the airway.
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Objective: Sputum biomarkers informative of current airway inﬂammation and predic-
tive of key clinical outcomes. Lung function, acute pulmonary exacerbations (APE), and
weight best predict survival in cystic ﬁbrosis (CF); however, underlying mechanisms
are not well understood. Alternative biomarkers of current disease state predictive of
future events might identify disease mechanisms, treatment targets and trial endpoints
and provide objective clinical monitoring tools. No such biomarker has been found in
CF.
Methods: With IRB approval, data were collected on 97 non-transplanted sputum-
producing adults, March 2004 to April 2011 in observational and validation cohorts for
up to 7 years. Granulocyte macrophage colony stimulating factor (log pg/ml, GMCSF)
and high-mobility group box-1 protein (log ng/ml, HMGB-1) measurements were used
to predict outcomes.
Results: After multivariate modeling and validation, only HMGB-1 (mean [SD], 5.84
[1.75]) predicts time-to-next APE (hazard ratio [HR] = 1.56, p= 0.005), number of
future APE (regression coefﬁcient [RC]=0.338, p< 0.001) and time-to-lung transplant
or death (HR= 1.59, p = 0.02). GMCSF (4.8 [1.26]) correlates with APE-associated
drops in FEV1% (RC=−10.8, p< 0.001).
Conclusions: In CF sputum, HMGB-1 predicts future APE and time-to-lung transplant
or death, potentially because it mediates long-term airway inﬂammation. High APE-
associated GMCSF identiﬁes patients with large acute declines in FEV1%. These
biomarkers are potential clinical tools providing laboratory-based objective support for
hospitalization and long term care. They may be treatment targets for slowing disease
progression and reducing short-term severity in CF.
